REGM™RenalEpithelialCellGrowthMediumBulletKit™

ProductOverview:

REGM™RenalEpithelialCellGrowthMediumisformulatedtomaintainandexpandmostrenalepithelialcells.REGM™contains0.5%serum.

MsGM™MesangialCellGrowthMedium;isformulatedforthegrowthofrenalmesangialcells.MsGM™contains5%serum.

Recommended:Lonza"s HumanRenalCells

SelectReferences: 

• DiabeticNephropathy isachronic,progressiverenaldisease/diabetickidneydiseasethatdevelopsinapproximatelyonethirdofpeoplewithdiabetes. Inastudy,Lonza’shumanproximaltubularepithelialcellswereculturedinrespectivemedia(REGM).ThegroupinvestigatedtheroleofKLK1(kallikrein)intubularpro-inflammatoryresponsesinculturedhumanRPTECandexaminedtheroleofPAR-4(Protease-ActivatedReceptor4)activationinKLK1-mediatedsignalinginthedevelopmentofDN. YiuWH,WongDW,ChanLY,LeungJC,ChanKW,LanHY,LaiKN,TangSC.TissueKallikreinMediatesPro-InflammatoryPathwaysandActivationofProtease-ActivatedReceptor-4inProximalTubularEpithelialCells.PLoSONE(2014);9(2):e88894
• RenalGraftResearch: Invitrorenalepithelialcellculturemodelshaveprovidedagreatdealofinformationabouttheoutcomeofrenalclinicaltransplantationmodels.InastudycarriedoutusingLonza’sPrimaryHumanRenalProximalTubularEpithelialcellsmaintainedinREGM^TMrenalepithelialgrowthmedia(cat#CC-2553&CC-3190respectively),thegroupstudytheeffectsofHCMV(Humancytomegalovirus)infectiononrenalcells.MasakoShimamura,JoanneE.Murphy-UllrichandWilliamJ.Britt.HumanCytomegalovirusInducesTGF-β1ActivationinRenalTubularEpithelialCellsafterEpithelial-to-MesenchymalTransition.PLoSPathogens.(2010);6(11):e1001170

龙沙生物技术有限公司于2019年05月10日成立。法定代表人David Johann Wach，公司经营范围包括：生物技术开发服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术推广服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术咨询、交流服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术转让服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;医学研究和试验发展（人体干细胞、基因诊断与治疗技术除外）;药品研发（人体干细胞、基因诊断与治疗技术除外）;货物进出口(涉及外资准入特别管理规定和许可审批的商品除外);技术进出口;贸易代理;商品批发贸易（涉及外资准入特别管理规定和许可审批的商品除外）;生物药品制造;化学药品原料药制造;化学药品制剂制造等。